Cardiovascular Nanomedicine

Dear Colleagues,

Cardiovascular nanomedicine (CVN) is a rapidly expanding field of medical nanotechnology. Nanoparticle (NP)-based drugs and diagnostic agents are now routinely utilized in clinical settings. One of the main advantages of nanoparticle-based agents is the controlled and targeted delivery to diseased tissues. Thus, efficacy is increased and classical side-effects are reduced. However, unexpected side-effects, mostly hypersensitivity reactions (HSRs) that also represent regulatory issues, appear. Among HSRs, complement-activation-related pseudoallergy (CARPA) is one with special human relevance.

Cardiovascular diseases (CVDs) are the most significant health problem in the world. Diseases of the heart as well as the vascular system belong to this discipline. While treatment with nanomedicines is well established for oncological and systemic fungal diseases, CVN is still the route ahead. Various NPs have been used for improving the features of existing CVD medications, while others for controlled delivery of new drugs. Another approach is to develop NP-based diagnostic agents for CVDs, e.g., superparamagnetic iron oxide nanoparticles (SPIONs) for plaques. However, most of these activities are still in the preclinical or early clinical trial phase. There is still long way to go before translational research can implement new CVD therapeutic and diagnostic strategies into clinical practice, and both efficacy and safety issues will first need to be addressed.

This Special Issue of Nanomaterials invites original research articles as well as review articles that will stimulate the continuing efforts in this exciting and continuously expanding field.

Dr. László Dézsi
Dr. Iwona Cicha
Prof. Dr. János Szebeni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Cardiovascular nanomedicine
• Cardiovascular disease
• Nanoparticle design
• SPIONs
• Controlled delivery
• Diagnostic agents
• Clinical translation
• Nanosafety
• Hypersensitive reactions
• Regulatory issues